SCHEMBL8395605

SCHEMBL8395605

CC(C)NC(=O)OC1CCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.50
TSHR P16473 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 1/20 0.46
KCNA3 P22001 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
DPP4 P27487 2/20 0.39
CYP19A1 P11511 1/20 0.37
IDO1 P14902 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8243916 0.96 EPHX1 (0.55) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL11153395 0.94 EPHX1 (0.58) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL14501550 0.93 EPHX1 (0.47) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL19958443 0.85 CYP3A4 (0.43) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL16669575 0.84 CHRM3 (0.42) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL22859960 0.84 EPHX1 (0.45) EPHX1TSHRCYP3A4CYP2C19KCNA3
SCHEMBL20069009 0.83 CHRM3 (0.46) EPHX1TSHRCYP3A4CYP2C19ALDH1A1
SCHEMBL18727001 0.82 EPHX1 (0.50) EPHX1TSHRCYP3A4CYP2C19ALDH1A1
SCHEMBL15058008 0.81 SMN1; SMN2 (0.50) EPHX1TSHRCYP3A4CYP2C19ALDH1A1
SCHEMBL15058009 0.81 SMN1; SMN2 (0.50) EPHX1TSHRCYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) 2025-11-18 US disclosed
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
WO-2025090658-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-05-01 WO disclosed
EP-3749355-B1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME UNIV MIAMI (US) 2024-07-03 EP disclosed
US-11649214-B2 Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same UNIVERSITY OF MIAMI (US) 2023-05-16 US disclosed
US-11649214-B2 Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same UNIVERSITY OF MIAMI (US) 2023-05-16 US disclosed
US-20210171469-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME UNIVERSITY OF MIAMI 2021-06-10 US disclosed
WO-2019157065-A9 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME UNIVERSITY OF MIAMI (US) 2020-10-29 WO disclosed
WO-2019157065-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME UNIVERSITY OF MIAMI (US) 2019-08-15 WO disclosed
US-20130060013-A1 Compounds useful for treating neurodegenerative disorders SATORI PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2011-10-20 US disclosed
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS SATORI PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110098293-A1 Inhibitors of Protein Tyrosine Kinase Activity OTSUKA PHARMACEUTICAL CO. LTD. (JP) 2011-04-28 US disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 EPHX1 4138/4885TSHR 2513/4885CYP3A4 2478/4885
US-20210171469-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX KINASE (\"NACK\") AND METHODS FOR USE OF THE SAME CHUK, NOTCH1, NUAK1 EPHX1 4113/4885TSHR 3424/4885CYP3A4 3363/4885
US-20110257100-A1 Inhibitors of Protein Tyrosine Kinase Activity ERBB2, ABL1, FLT1 EPHX1 3242/4885TSHR 1143/4885CYP3A4 4737/4885
US-20130060013-A1 Compounds useful for treating neurodegenerative disorders SNCA, HTT, CLN6 EPHX1 984/4885TSHR 4547/4885CYP3A4 4139/4885
US-11649214-B2 Inhibitors of the notch transcriptional activation complex kinase (“NACK”) and methods for use of the same NOTCH1, CHUK, CBFB EPHX1 3729/4885TSHR 3675/4885CYP3A4 3769/4885
US-20110098293-A1 Inhibitors of Protein Tyrosine Kinase Activity ABL1, ERBB2, TYRO3 EPHX1 3028/4885TSHR 1058/4885CYP3A4 4765/4885
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS CLN6, NLN, ACHE EPHX1 863/4885TSHR 4713/4885CYP3A4 4227/4885
US-12473291-B2 Benzodiazepine compound, preparation method therefor, and use thereof in medicine GABRA1, GABRA4, GABRR1 EPHX1 2991/4885TSHR 1808/4885CYP3A4 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.